Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.
about
Myasthenia gravis: past, present, and futureRisk Factors Associated with Cognitive Decline after Cardiac Surgery: A Systematic ReviewIn Vitro Selection of Cancer Cell-Specific Molecular Recognition Elements from Amino Acid LibrariesDissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombusA humanized single-chain variable fragment antibody against beta3 integrin in Escherichia coliMannan-binding lectin in cardiovascular disease.Activation of complement factor B contributes to murine and human myocardial ischemia/reperfusion injury.Murine complement interactions with Pseudomonas aeruginosa and their consequences during pneumoniaCardiac protection by pharmacological modulation of inflammation.Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I.Complement and its implications in cardiac ischemia/reperfusion: strategies to inhibit complement.Novel complement inhibitor limits severity of experimentally myasthenia gravisProphylaxis and treatment of Alzheimer's disease by delivery of an adeno-associated virus encoding a monoclonal antibody targeting the amyloid Beta protein.Complement and systemic lupus erythematosus.The evolution of cardiopulmonary bypass: lessons to be learned.Complement in ischemia reperfusion injury.Artificial surface-induced inflammation relies on complement factor 5: proof from a deficient person.Polyglycolic acid-induced inflammation: role of hydrolysis and resulting complement activation.Ischaemia-reperfusion is an event triggered by immune complexes and complement.Role for the alternative complement pathway in ischemia/reperfusion injuryInduction and detection of disturbed homeostasis in cardiopulmonary bypass.Activation of the complement system: a crucial link between inflammation and atherosclerosis?Novel C5a regulators in inflammatory disease.Modulation of systemic inflammatory response after cardiac surgery.Genetic susceptibility to inflammatory injury and various adverse outcomesComplement activity and pharmacological inhibition in cardiovascular disease.Plasma troponin levels after cardiac surgery vs after myocardial infarction.Neuroprotection during cardiac surgery.Natural IgM-mediated innate autoimmunity: a new target for early intervention of ischemia-reperfusion injury.Pharmacologic strategies for combating the inflammatory response.Anticomplement therapy.Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection.Taking complement to the clinic--has the time finally come?Anticoagulation and coagulation management for ECMO.Effect of lornoxicam in lung inflammatory response syndrome after operations for cardiac surgery with cardiopulmonary bypass.Lung inflammatory response syndrome after cardiac-operations and treatment of lornoxicam.Complement factor 5 blockade reduces porcine myocardial infarction size and improves immediate cardiac function.Role of complement and perspectives for intervention in ischemia-reperfusion damage.Ulex europaeus agglutinin II (UEA-II) is a novel, potent inhibitor of complement activation.BrkA protein of Bordetella pertussis inhibits the classical pathway of complement after C1 deposition.
P2860
Q24678531-D041FAC1-199D-4384-B409-254B5FFF031EQ26780541-ACE7E1C5-05FD-442E-AD59-0D049795869EQ26782129-F0FA3C56-F90B-4B97-BC6C-E69EF6E86411Q33389941-1D301132-3198-45AD-BA6F-7625435FC93FQ33398622-0CA9B83A-2817-4F7A-9FCD-CBDD38EBEA75Q33616097-37BBE93B-9540-4C28-9E1E-2D6D0561D6DAQ33852943-651B1C31-E9AB-4C5F-A623-59E8CCCAFD3DQ34129468-678DB52C-0B88-4A3D-80D9-E6E4291E39E0Q34481804-9FE0A767-CD25-4EAD-9DC9-22F415BBB804Q34542843-0A54F297-92BA-4BF2-8651-A56062810102Q34570640-4BB47E51-90D8-49E2-93EB-C5D7E9112112Q34604158-4B5C9CE8-7D51-4F46-B9DC-E8D10253DD0EQ34650215-5DE99C4B-409D-4B37-86C6-CAF5C272B5D1Q34731255-1C12D572-30F7-45D9-BDC7-63C0DD2FF6CFQ34760349-3AE358A5-FA88-4E68-95E3-54BFF6908FEEQ35053536-3CD1E845-8181-4D52-AEE6-AA6847CB9EBFQ35069163-2A8B1600-E87E-4423-BAAD-293B4051A808Q35585813-FDC7ACA2-DE7E-41E2-B567-F3C80821EE28Q35597392-D84AE81D-4012-4808-8187-347122832862Q35748956-CA0E0E6C-2953-44DB-AB9D-390198498BFEQ35929339-FF261E03-9E54-41A5-A481-8266167A31BFQ35988004-DD14A628-1834-46A8-8BDE-796947A26F27Q36196446-FBDA9CC8-C8F8-4C07-AF4C-80FD0AC298EBQ36320195-35CE85DC-9B64-4966-93ED-4A72C51A15EFQ36374968-11525501-9799-4A19-A091-120337389758Q36405114-45D655F4-8CB5-4CB2-87E5-0EDEED8ED8E8Q36665967-2C5489F1-52B6-4E0F-9D4F-7C00A12727DAQ36902871-3011EA7B-B077-4868-B406-525E14587DDDQ36960513-B551BD58-024E-46EC-9EC1-3D16C327594DQ37092150-30131F68-0D60-4A71-934B-46622B08C8D9Q37307880-68711ACD-2F22-4BB3-8F84-C05AF42EFEE2Q37441972-9CE5C41C-9FDB-4B9D-A204-4C87130D23A4Q37480050-3A27D189-42D1-4E4E-9829-565A994EF815Q37600544-E6326604-328D-4175-83FE-FCC025BD9A5AQ37663883-C65B3264-08C1-491E-89D9-C72915FFC06BQ37663916-9B5D323F-604B-474F-8ACA-C706D4FD5187Q37680021-73A41632-C45A-4218-9186-EC7C3DED3A4CQ37831329-1166E3EC-D8C2-4AFB-80DA-B47B27B706EEQ38271637-D3CCCB0F-F788-45B2-A6C4-12706F2E9015Q39519868-E315E2B7-5B76-4FEB-88AD-6CD558E4F4E2
P2860
Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Pharmacology and biological ef ...... y with cardiopulmonary bypass.
@en
Pharmacology and biological ef ...... y with cardiopulmonary bypass.
@nl
type
label
Pharmacology and biological ef ...... y with cardiopulmonary bypass.
@en
Pharmacology and biological ef ...... y with cardiopulmonary bypass.
@nl
prefLabel
Pharmacology and biological ef ...... y with cardiopulmonary bypass.
@en
Pharmacology and biological ef ...... y with cardiopulmonary bypass.
@nl
P2093
P921
P1433
P1476
Pharmacology and biological ef ...... y with cardiopulmonary bypass.
@en
P2093
Collard CD
Elefteriades J
P304
P356
10.1161/01.CIR.100.25.2499
P407
P577
1999-12-01T00:00:00Z